文献速递抗栓抗凝管理药物不良反应与药物警戒

华法林与直接口服抗凝药癌症风险比较:英格兰与香港人群队列研究

Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong.
PubMed 文献 · Drug Saf · 2026-01-19

该研究基于英格兰和香港人群数据库,采用新用户活性对照队列设计,比较房颤患者使用华法林与直接口服抗凝药的癌症风险。两地均未发现华法林与总体癌症风险相关;香港亚组中部分部位特异性癌症风险有差异,但未在英格兰重复。

要点

  • 与直接口服抗凝药相比,华法林未显示总体癌症风险差异。
  • 香港亚组中华法林与部分部位特异性癌症风险相关,英格兰未重复。
  • 部位特异性癌症信号需在其他独立数据集中进一步验证。

核心结论

  • 与直接口服抗凝药相比,华法林未显示对癌症的保护作用。
  • 香港观察到的部位特异性癌症风险差异未在英格兰重复,需进一步研究。

研究设计与样本

  • 基于英格兰和香港人群数据库的新用户活性对照队列研究。
  • 纳入2011年1月1日至2019年12月31日期间首次接受抗凝治疗的≥18岁房颤患者。

主要发现

  • 英格兰总体癌症风险:HR=1.03,95%CI 0.94-1.13。
  • 香港总体癌症风险:HR=0.89,95%CI 0.79-1.01。
  • 香港亚组中,华法林与女性乳腺癌(HR=0.49,95%CI 0.30-0.79)、卵巢癌(HR=0.07,95%CI 0.01-0.58)、胰腺癌(HR=0.46,95%CI 0.22-0.96)风险降低及肾癌风险升高(HR=3.57,95%CI 1.64-7.76)相关,但英格兰未重复。

临床怎么用

  • 临床选择华法林或直接口服抗凝药时,不应以癌症预防作为决策依据。
  • 对香港研究中提示的部位特异性癌症信号应保持关注,但需更多独立数据验证。

局限性

  • 部位特异性癌症风险差异仅在香港观察到,未在英格兰重复,可能受地区或人群差异影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. OBJECTIVE: We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). METHODS: We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011-31/12/2019 were involved. RESULTS: No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94-1.13; Hong Kong: HR = 0.89, 95% CI 0.79-1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30-0.79), ovarian (HR = 0.07, 95% CI 0.01-0.58), and pancreatic (HR = 0.46, 95% CI 0.22-0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64-7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. CONCLUSIONS: This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Wang Z, Yu Q, Matthewman J, et al. Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong. Drug Saf. 2026. PMID: 41553598. doi:10.1007/s40264-025-01645-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。